These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 22999134)

  • 1. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.
    Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
    Value Health; 2012; 15(6):843-50. PubMed ID: 22999134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7.
    Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
    Med Decis Making; 2012; 32(5):733-43. PubMed ID: 22990088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2.
    Roberts M; Russell LB; Paltiel AD; Chambers M; McEwan P; Krahn M;
    Value Health; 2012; 15(6):804-11. PubMed ID: 22999129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.
    Caro JJ; Briggs AH; Siebert U; Kuntz KM;
    Value Health; 2012; 15(6):796-803. PubMed ID: 22999128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2.
    Roberts M; Russell LB; Paltiel AD; Chambers M; McEwan P; Krahn M;
    Med Decis Making; 2012; 32(5):678-89. PubMed ID: 22990083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4.
    Karnon J; Stahl J; Brennan A; Caro JJ; Mar J; Möller J;
    Value Health; 2012; 15(6):821-7. PubMed ID: 22999131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The view of a model user on the ISPOR-SMDM modeling good research task force report.
    Berger ML
    Value Health; 2012; 15(6):794-5. PubMed ID: 22999127
    [No Abstract]   [Full Text] [Related]  

  • 11. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making.
    Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Mullins CD
    Value Health; 2017 Sep; 20(8):1003-1008. PubMed ID: 28964430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3.
    Siebert U; Alagoz O; Bayoumi AM; Jahn B; Owens DK; Cohen DJ; Kuntz KM;
    Value Health; 2012; 15(6):812-20. PubMed ID: 22999130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II.
    Cox E; Martin BC; Van Staa T; Garbe E; Siebert U; Johnson ML
    Value Health; 2009; 12(8):1053-61. PubMed ID: 19744292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.
    Briggs AH; Weinstein MC; Fenwick EA; Karnon J; Sculpher MJ; Paltiel AD;
    Value Health; 2012; 15(6):835-42. PubMed ID: 22999133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.
    Jaime Caro J; Eddy DM; Kan H; Kaltz C; Patel B; Eldessouki R; Briggs AH;
    Value Health; 2014 Mar; 17(2):174-82. PubMed ID: 24636375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.
    Weinstein MC; O'Brien B; Hornberger J; Jackson J; Johannesson M; McCabe C; Luce BR;
    Value Health; 2003; 6(1):9-17. PubMed ID: 12535234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM).
    Willis M; Johansen P; Nilsson A; Asseburg C
    Pharmacoeconomics; 2017 Mar; 35(3):375-396. PubMed ID: 27838913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.